Incidence and survival of therapy related myeloid neoplasm in United States

• Published in: Leukemia research 2018-08, Vol.71, p.95-99
• Main Authors: Guru Murthy, Guru Subramanian, Hamadani, Mehdi, Dhakal, Binod, Hari, Parameswaran, Atallah, Ehab
• Format: Article
• Language: English
• Subjects: Incidence; Leukemia; Myelodysplasia; SEER; Survival; Therapy
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2018.07.013

•Incidence of therapy related myeloid neoplasm is increasing in US.•Its incidence is influenced by demographic factors such as age and race.•Survival of this malignancy is dismal, although is improving in the current era.•Novel therapies are needed to improve the outcomes. Therapy related myeloid neoplasm (t-MN) is an emerging challenge in the current era. However, real world data on its incidence and survival at the population level remains sparse. Using Surveillance Epidemiology and End Results (SEER-18) database, we identified patients aged ≥20 years with pathologically confirmed t-MN diagnosed between the years 2001–2014 and actively followed. Incidence rate per 100,000 population and incidence rate ratio (IRR) were calculated. Overall survival (OS) was calculated by Kaplan-Meier method with determinants analyzed by Cox proportional hazard regression method. A total of 1093 patients with a median age of 65 years were identified. Overall incidence of t-MN was 0.13 cases/100,000 population and showed significant variations with age, race and the period of diagnosis. Two year OS significantly declined with increasing age (51.3% in age group 20–39, 33.9% in age group 40–59, 19.3% in age group 60–79 and 0% in age ≥ 80, p